Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer

Launched by UMEÅ UNIVERSITY · Apr 26, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how well different treatments work for people with locally advanced pancreatic cancer, which means the cancer is not yet spread to distant parts of the body but is still difficult to remove with surgery. The main goals of the study are to see how long patients can live after treatment, how their quality of life is affected, and how many patients can have surgery to remove their tumors. Researchers are currently looking for participants aged 65 to 74 who have been diagnosed with pancreatic cancer that falls into specific categories outlined by national guidelines.

To be eligible for the trial, participants must have a confirmed diagnosis of pancreatic cancer that is classified as either borderline resectable or locally advanced. However, individuals with certain other types of tumors, those with cancer that has spread to other parts of the body, or those younger than 18 years are not eligible to join. Participants will receive treatment and care, and they can expect to be closely monitored throughout the study. This trial could provide valuable information that may help improve treatment options for others facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed or suspected invasive pancreatic primary tumor
• • Tumor classified as borderline resectable or locally advanced disease according to NCCN guidelines
• Exclusion Criteria:
• • Suspected endocrine tumor
• • Suspected non-pancreatic periampullary tumor
• • Distant metastasis
• • Age \< 18 years
• • Patient unable to understand verbal or written information interfering with informed consent or treatment
• • Mental or organic disorder interfering with informed consent or treatments